Glen Morgan1, Cathy Backinger, Caryn Lerman, Francis Vocci. 1. Tobacco Control Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20852, USA. gmorgan@nih.gov
Abstract
OBJECTIVE: To review the current state of the science in medication development for nicotine dependence and to identify important areas for future research. METHODS: The National Cancer Institute and the National Institute on Drug Abuse convened a conference focused on translational approaches to the development, evaluation, and delivery of medications for the treatment of tobacco dependence. RESULTS: Future research directions include investigations of the efficacy of novel compounds and new applications for existing medications; pharmacogenetic trials of nicotine dependence treatments; and studies of the molecular, neural, and behavioral mechanisms of action of efficacious medications. CONCLUSIONS: Medication development for the treatment of tobacco dependence remains a scientific and public health priority.
OBJECTIVE: To review the current state of the science in medication development for nicotine dependence and to identify important areas for future research. METHODS: The National Cancer Institute and the National Institute on Drug Abuse convened a conference focused on translational approaches to the development, evaluation, and delivery of medications for the treatment of tobacco dependence. RESULTS: Future research directions include investigations of the efficacy of novel compounds and new applications for existing medications; pharmacogenetic trials of nicotine dependence treatments; and studies of the molecular, neural, and behavioral mechanisms of action of efficacious medications. CONCLUSIONS: Medication development for the treatment of tobacco dependence remains a scientific and public health priority.
Authors: Margot A Cousin; Jon O Ebbert; Amanda R Wiinamaki; Mark D Urban; David P Argue; Stephen C Ekker; Eric W Klee Journal: PLoS One Date: 2014-03-21 Impact factor: 3.240